Athersys, Inc. Press Releases https://www.athersys.com/generated by Q4Sun, 19 Apr 2026 22:38:14 -0400Copyright Q4 Inc. All rights reserved.Athersys Reports Third Quarter 2023 Financial Results and Business Highlightsb8e77b24-adb9-4cd3-b8ea-77431a54c647https://www.athersys.com/investors/press-releases/press-release-details/2023/Athersys-Reports-Third-Quarter-2023-Financial-Results-and-Business-Highlights/default.aspxThu, 16 Nov 2023 08:30:00 -0500Athersys Extends Near Term Liquidity with Proceeds from Warrant Inducement and Global ARDS License with Healios to Explore Strategic Alternativesdf38a831-3943-401c-99fb-b1dbb18a073fhttps://www.athersys.com/investors/press-releases/press-release-details/2023/Athersys-Extends-Near-Term-Liquidity-with-Proceeds-from-Warrant-Inducement-and-Global-ARDS-License-with-Healios-to-Explore-Strategic-Alternatives/default.aspxMon, 16 Oct 2023 16:52:00 -0400Athersys Reports Interim Analysis Results of MASTERS-2 Clinical Study with MultiStem in Ischemic Stroke, Signs Memorandum of Understanding (MOU) for Global ARDS License with Healios5a99196f-d472-412d-bb03-47e01502109bhttps://www.athersys.com/investors/press-releases/press-release-details/2023/Athersys-Reports-Interim-Analysis-Results-of-MASTERS-2-Clinical-Study-with-MultiStem-in-Ischemic-Stroke-Signs-Memorandum-of-Understanding-MOU-for-Global-ARDS-License-with-Healios/default.aspxTue, 10 Oct 2023 08:30:00 -0400Athersys Licenses its Animal Health Assets to Ardent Animal Health0ac8d30d-b78b-4990-a512-c0e7fdb6d813https://www.athersys.com/investors/press-releases/press-release-details/2023/Athersys-Licenses-its-Animal-Health-Assets-to-Ardent-Animal-Health/default.aspxTue, 03 Oct 2023 16:30:00 -0400Athersys Director Jane Wasman Appointed Board Chairf71b54d6-0bc5-4f2d-a373-717a20a642aehttps://www.athersys.com/investors/press-releases/press-release-details/2023/Athersys-Director-Jane-Wasman-Appointed-Board-Chair/default.aspxMon, 02 Oct 2023 17:04:00 -0400Grant Awarded to Newcastle University to Research Athersys’ MultiStem® in Machine Perfusion Prior to Kidney Transplantation047043a2-67dc-47bc-b9dd-44b2cc88949ehttps://www.athersys.com/investors/press-releases/press-release-details/2023/Grant-Awarded-to-Newcastle-University-to-Research-Athersys-MultiStem-in-Machine-Perfusion-Prior-to-Kidney-Transplantation/default.aspxWed, 06 Sep 2023 14:45:00 -0400Athersys, Inc. Announces Pricing of $3.5 Million Public Offering0bd3322b-3c58-4eff-ae94-c9707a396d21https://www.athersys.com/investors/press-releases/press-release-details/2023/Athersys-Inc.-Announces-Pricing-of-3.5-Million-Public-Offering/default.aspxThu, 17 Aug 2023 21:30:00 -0400Athersys Reports Second Quarter 2023 Financial Results and Business Highlights0988db32-9c8d-42df-bcc6-67cd1fa0f742https://www.athersys.com/investors/press-releases/press-release-details/2023/Athersys-Reports-Second-Quarter-2023-Financial-Results-and-Business-Highlights/default.aspxWed, 16 Aug 2023 17:01:00 -0400Athersys Appoints Neema Mayhugh, PhD to its Board of Directors05ddc452-caff-426a-aa65-a678b1363765https://www.athersys.com/investors/press-releases/press-release-details/2023/Athersys-Appoints-Neema-Mayhugh-PhD-to-its-Board-of-Directors/default.aspxFri, 11 Aug 2023 08:00:00 -0400Athersys to Host Business Update Conference Call on August 9thad6c025f-a0f0-452c-93f7-2fa2d4fda3c7https://www.athersys.com/investors/press-releases/press-release-details/2023/Athersys-to-Host-Business-Update-Conference-Call-on-August-9th/default.aspxMon, 31 Jul 2023 13:38:00 -0400